
Alpine Immune Sciences ALPN
Country |
|
IPO year |
2015 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
50 M |
Market Cap[1] |
$ 2.17 B |
EBITDA (LTM) |
- |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Corvus Pharmaceuticals
CRVS
|
$ 9.52 | 5.01 % | $ 752 M | Nasdaq Global Market | ||
|
Vascular Biogenics Ltd.
VBLT
|
- | -8.77 % | $ 12.4 M | Nasdaq Global Select Market | ||
|
Berkeley Lights
BLI
|
- | -7.31 % | $ 87 M | Nasdaq Global Select Market | ||
|
Histogen
HSTO
|
- | 31.6 % | $ 2.12 M | Nasdaq Global Select Market | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
$ 24.02 | 0.39 % | $ 3.64 B | Nasdaq Global Select Market,SPB | ||
|
Denali Therapeutics
DNLI
|
$ 17.61 | 2.63 % | $ 3.04 B | Nasdaq Global Select Market,SPB | ||
|
Achieve Life Sciences
ACHV
|
$ 6.38 | 0.79 % | $ 278 M | Nasdaq Capital Market | ||
|
ImmunoGen
IMGN
|
- | - | $ 7.92 B | Nasdaq Global Select Market | ||
|
Precision BioSciences
DTIL
|
$ 5.77 | 2.32 % | $ 74 M | Nasdaq Global Select Market | ||
|
Editas Medicine
EDIT
|
$ 2.35 | 7.49 % | $ 209 M | Nasdaq Global Select Market,SPB | ||
|
Crinetics Pharmaceuticals
CRNX
|
$ 84.95 | 0.13 % | $ 7.99 B | Nasdaq Global Select Market | ||
|
Agios Pharmaceuticals
AGIO
|
$ 31.32 | 4.36 % | $ 1.82 B | Nasdaq Global Select Market,SPB | ||
|
Enanta Pharmaceuticals
ENTA
|
$ 11.1 | 2.59 % | $ 237 K | Nasdaq Global Select Market,SPB | ||
|
Exelixis
EXEL
|
$ 62.23 | 0.06 % | $ 16.9 B | Nasdaq Global Select Market,SPB | ||
|
EyePoint Pharmaceuticals
EYPT
|
$ 2.99 | 4.32 % | $ 219 K | Nasdaq Global Market | ||
|
AIM ImmunoTech
AIM
|
$ 0.17 | 1.53 % | $ 275 K | NYSE American | ||
|
Cidara Therapeutics
CDTX
|
- | - | $ 1.41 B | Nasdaq Global Market | ||
|
Iterum Therapeutics
ITRM
|
- | - | $ 591 K | Nasdaq Global Select Market | ||
|
Akebia Therapeutics
AKBA
|
$ 0.67 | 0.14 % | $ 172 M | Nasdaq Global Market | ||
|
GlaxoSmithKline plc
GSK
|
$ 49.51 | 1.0 % | $ 201 B | NYSE | ||
|
GT Biopharma
GTBP
|
$ 7.03 | 18.52 % | $ 38.8 M | Nasdaq Capital Market | ||
|
Heron Therapeutics
HRTX
|
$ 0.36 | 4.01 % | $ 60 M | Nasdaq Global Select Market,SPB | ||
|
Johnson & Johnson
JNJ
|
$ 255.56 | 0.86 % | $ 615 B | NYSE,SPB | ||
|
Akari Therapeutics, Plc
AKTX
|
$ 8.18 | 19.02 % | $ 551 B | Nasdaq Capital Market | ||
|
Clovis Oncology
CLVS
|
- | -7.23 % | $ 13 M | Nasdaq Global Select Market | ||
|
Arcutis Biotherapeutics
ARQT
|
$ 28.82 | 10.19 % | $ 3.67 B | Nasdaq Global Select Market,SPB | ||
|
Aldeyra Therapeutics
ALDX
|
$ 0.7 | 0.62 % | $ 42 M | Nasdaq Global Select Market | ||
|
Kura Oncology
KURA
|
$ 9.08 | 0.94 % | $ 796 M | Nasdaq Global Select Market | ||
|
Concert Pharmaceuticals
CNCE
|
- | - | $ 401 M | Nasdaq Global Market | ||
|
Checkmate Pharmaceuticals
CMPI
|
- | - | $ 231 M | Nasdaq Global Market | ||
|
Kaleido Biosciences
KLDO
|
- | -3.69 % | $ 12.4 M | Nasdaq Global Select Market | ||
|
Cyclerion Therapeutics
CYCN
|
$ 34.99 | 3.77 % | $ 147 M | Nasdaq Global Select Market | ||
|
Alector
ALEC
|
$ 1.84 | 6.02 % | $ 190 M | Nasdaq Global Select Market,SPB | ||
|
ObsEva SA
OBSV
|
- | -15.52 % | $ 10.5 M | Nasdaq Global Select Market | ||
|
Kronos Bio
KRON
|
- | 1.49 % | $ 50.8 M | Nasdaq Global Select Market | ||
|
Landos Biopharma
LABP
|
- | 0.58 % | $ 144 M | Nasdaq Global Market | ||
|
PhaseBio Pharmaceuticals
PHAS
|
- | 7.4 % | $ 6.29 M | Nasdaq Global Market | ||
|
Provention Bio
PRVB
|
- | - | $ 2.37 B | Nasdaq Global Select Market | ||
|
Poseida Therapeutics
PSTX
|
- | - | $ 857 M | Nasdaq Global Select Market | ||
|
PolarityTE
PTE
|
- | -0.82 % | $ 1.78 M | Nasdaq Capital Market | ||
|
Reata Pharmaceuticals
RETA
|
- | - | $ 6.29 B | Nasdaq Global Market,SPB | ||
|
Virpax Pharmaceuticals
VRPX
|
- | -45.12 % | $ 2.85 M | Nasdaq Global Select Market | ||
|
ALX Oncology Holdings
ALXO
|
$ 1.06 | 6.0 % | $ 56.9 M | Nasdaq Global Select Market,SPB | ||
|
Lineage Cell Therapeutics
LCTX
|
$ 0.98 | 0.09 % | $ 226 M | NYSE American | ||
|
Stealth BioTherapeutics Corp
MITO
|
- | - | $ 23.9 M | Nasdaq Global Select Market | ||
|
Satsuma Pharmaceuticals
STSA
|
- | -0.9 % | $ 36.5 M | Nasdaq Global Market | ||
|
SpringWorks Therapeutics
SWTX
|
- | - | $ 3.48 B | Nasdaq Global Select Market,SPB | ||
|
Trevena
TRVN
|
- | -46.58 % | $ 31.8 M | Nasdaq Capital Market | ||
|
Oncorus
ONCR
|
- | -8.54 % | $ 3.19 M | Nasdaq Global Market | ||
|
OncoSec Medical Incorporated
ONCS
|
- | 31.87 % | $ 1.61 M | Nasdaq Global Select Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.